SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

✍ Scribed by Clamp, A R; Mäenpää, J; Cruickshank, D; Ledermann, J; Wilkinson, P M; Welch, R; Chan, S; Vasey, P; Sorbe, B; Hindley, A

• Book ID: 109998691
• Publisher: Nature Publishing Group
• Year: 2005
• Tongue: English
• Weight: 119 KB
• Volume: 94
• Category: Article
• ISSN: 0007-0920
• DOI: 10.1038/sj.bjc.6602910